Yahoo
NSE - Delayed Quote INR

Lincoln Pharmaceuticals Limited (LINCOLN.NS)

520.85 +7.15 (+1.39%)
At close: 3:30:00 PM GMT+5:30
View in AlphaSpace Currency in INR All numbers in thousands
Financial statements have been upgraded
A new layout with more detail in every statement.
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
7,222,265 6,622,872 6,152,475 5,712,178 5,049,547
Cost of Revenue
-3,480,703 -3,123,052 -2,926,394 -2,800,193 -2,430,877
Gross Profit
3,741,562 3,499,820 3,226,081 2,911,985 2,618,670
Selling, General and Administrative Expenses
-1,276,788 -2,112,281 -1,848,629 -1,603,213 -1,428,454
Operation and Maintenance Expenses
-76,629 -76,629 -57,298 -47,388 -43,490
Depreciation, Amortization and Depletion
-151,721 -144,996 -128,990 -106,247 -91,661
Taxes Other Than Income Taxes
-23,987 -23,987 -30,324 -25,422 -29,020
Provision Expense/Write-Back
8,752 8,752 2,867 -6,495 1,776
Other Income/Expense, Operating
-1,469,077 -292,971 -268,785 -226,997 -221,066
Operating Income/Expenses
-2,897,586 -2,642,112 -2,331,159 -2,015,762 -1,811,915
Total Operating Profit/Loss
843,976 857,708 894,922 896,223 806,755
Total Net Finance Income/Expense
-11,491 65,723 53,373 55,582 41,411
Net Investment Income
228,404 228,404 149,666 273,600 159,197
Irregular Income/Expenses
1,291 1,291 -6,113 -2,980 -2,563
Other Income/Expense, Non-Operating
447,488 3,124 38 -- --
Non-Operating Income/Expenses, Total
435,997 298,542 196,964 326,202 198,045
Pretax Income
1,279,973 1,156,250 1,091,886 1,222,426 1,004,798
Provision for Income Tax
-311,021 -277,312 -268,422 -289,377 -275,805
Net Income from Continuing Operations
968,952 878,938 823,464 933,049 728,993
Net Income after Extraordinary Items and Discontinued Operations
968,952 878,938 823,464 933,049 728,993
Net Income after Non-Controlling/Minority Interests
968,952 878,938 823,464 933,049 728,993
Net Income Available to Common Stockholders
968,952 878,938 823,464 933,049 728,993
Diluted Net Income Available to Common Stockholders
968,952 878,938 823,464 933,049 728,993
Common Dividend per Share
1.80 1.80 1.80 1.80 1.50
Basic EPS
48.38 43.88 41.11 46.58 36.40
Diluted EPS
48.38 43.88 41.11 46.58 36.40
Basic Weighted Average Shares Outstanding
20,027.33 20,029.73 20,029.73 20,029.73 20,029.73
Diluted Weighted Average Shares Outstanding
20,027.33 20,029.73 20,029.73 20,029.73 20,029.73
Income Statement, Supplemental
EBIT
1,291,464 1,084,576 1,029,643 1,161,658 959,465
3/31/2023 - 12/17/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: